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Summary In this study, the immunohistochemical expression of a new inducible elastase inhibitor, SKALP (skin-derived anti-
leucoproteinase)/elafin, in the tissue of squamous cell carcinoma and uninvolved oesophageal mucosa was studied using a polyclonal rabbit
anti-serum against SKALP/elafin. The results were compared with the immunohistochemical staining of proliferating cell nuclear antigen
(PCNA) and the TUNEL assay in serial sections. In non-malignant oesophageal mucosa, the expression of SKALP/elafin was localized in the
cells of the stratified zone overlying the PCNA-positive basal zone. In oesophageal cancer, the incidence of the expression was significantly
related to the degree of the differentiation of the tumour. Characteristically, the expression was almost limited in tumour cell nests that had a
clear squamous phenotype. In tumour cell nests, the expression of SKALP/elafin was localized in the cells overlying PCNA-expressing cells
and no expression was found in the cells that expressed PCNA; DNA fragmentation was often observed in the same cell layers as those in
which SKALP/elafin immunoreactivity was found. This enzyme inhibitor is speculated to be involved in the induction of the cell differentiation
and apoptosis of human squamous cell carcinoma cells of the oesophagus.
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Squamous cell carcinoma (SCC) is the major histological type of
oesophageal cancer in Japan, being one of the most lethal
neoplasms of the digestive organs. At present, only limited
numbers ofpatients can be cured by conventional therapy, such as
surgical resection, irradiation and chemotherapy, one reason being
that oesophageal cancer has an extremely high potential for
invasion into the surrounding organs and for metastasis. Several
proteases produced by the cancer cell itself have been reported to
be associated with cancer invasion and metastasis (Liotta et al,
1980, 1986, 1991; Wooley, 1984; Nakajima et al, 1987; Reich
et al, 1988; Basset et al, 1990). Also several kinds of specific
inhibitors of such proteases have been shown to inhibit cancer
invasion and metastasis (Baker et al, 1990; Cajot et al, 1990;
Albini et al, 1991; Declerck et al, 1992; Kennedy, 1994;
Kobayashi et al, 1994, 1995). Hence, the protease inhibitors could
be considered to possess the potential to be a useful tool for the
development ofa new therapeutic method against cancer.
Recently, a new inducible elastase inhibitor, SKALP (skin-
derived antileucoproteinase) has been isolated from psoriatic skin
(Schalkwijk et al, 1990, 1993). SKALP has been shown to be a
heat-stable, cationic protein with an apparent molecular weight of
9-11 kDa. DNA of SKALP has been cloned and sequenced
(Schalkwijk et al, 1991) and has proved to be identical to elafin,
which is a similar epidermal protease inhibitor described by
Wiedow et al (1990). The expression of SKALP/elafin has not
been found in the cells ofnormal epidermis but is found in differ-
entiating cells of psoriasis and wound healing (Schalkwijk et al,
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1990, 1993). Differential expression has also been observed in a
number of epidermal tumours (Alkemade et al, 1993). However,
no information is available concerning the squamous cell carci-
noma ofthe oesophagus.
In this study, to elucidate the biological significance of this
enzyme inhibitor, the immunohistochemical expression of
SKALP/elafin in the tissues of squamous cell carcinoma and unin-
volvedoesophageal mucosa was examinedusing apolyclonal rabbit
anti-serum against SKALP/elafin. In addition, the evaluation ofthe
relationship between the immunohistochemical staining ofprolifer-
ating cell nuclear antigen (PCNA) and the TDT-mediated dUTP-
digoxigenin nick end labelling (TUNEL assay) and the expression
ofthis enzyme inhibitor was performedusing serial sections. This is
the first report to analyse the expression of SKALP/elafin in
squamous cell carcinoma ofthe human oesophagus.
MATERIALS AND METHODS
Isolation and purification of SKALP/elafin
The method ofthe isolation and purification ofSKALP/elafin both
from psoriatic scales and from cultured human keratinocytes has
been described previously (Schalkwijk et al, 1990, 1991). In brief,
psoriatic scales were homogenized in distilled water, yielding a
suspension that was boiled and centrifuged, followed by chloro-
form extraction and centrifugation. After concentration, the
preparation was further purified by chromatofocusing (PBE 118
column, triethylamine buffer) and affinity chromatography
[porcine pancreatic elastase coupled to cyanogen bromide-
activated Sepharose 4B, phosphate-buffered saline (PBS) washing
buffer and 0.1 M acetic acid eluting buffer]. Final purification was
by gel permeation chromatography on a Superdex-75 fast protein
liquid chromatography column. Extracts of cultured keratinocytes
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were prepared by sonication ofthe cells in distilled water and were
subjected to the Smart chromatography system (Superdex 75 PC
2.3/30 column). Anti-elastase activity in obtained fractions was
measured; relevant fractions were pooled and vacuum evaporated
to dryness.
Anti-SKALP/elafin serum
The method of the production of a polyclonal rabbit anti-
SKALP/elafin serum has been reported previously (Schalkwijk et
al, 1991; Alkemade et al, 1993). In brief, a rabbit was immunized
intracutaneously with highly purified SKALP/elafin that was
partially cross-linked with glutaraldehyde and emulsified in
Freund's complete adjuvant. A booster with the same preparation
was given after 2 weeks, and4 weeks later serum was collected via
standard methods. The specificity of the antiserum was validated
in functional assays and on Western blots, which showed that
(1) the immunohistochemical reactivity of antiserum could be
absorbed by SKALP/elafin and the elastase-inhibiting activity
could be absorbed by sepharose 4B-conjugated immunoglobulins
purified from anti-SKALP/elafin serum by protein A chromatog-
raphy; and that (2) the band stained on a Western blot corre-
sponded with a band of anti-elastase activity eluted from the
SDS-PAGE gel as shown previously (Schalkwijk et al, 1991;
Alkemade et al., 1993).
Tissues
A total of 34 tissues of oesophageal carcinoma as well as
uninvolved oesophageal mucosa were obtained from surgical
specimens resected at the Department of Surgery II, Kumamoto
University Hospital, between 1989 and 1994 without any preoper-
ative treatment. The patients consisted of30 men and four women.
Their average age was 64.1 years.
All specimens were immediately fixed in 10% (v/v) buffered
formalin and embedded in paraffin. Four-micron-thick sections
were prepared from each sample and processed for immunohisto-
chemistry with anti-SKALP/elafin serum and MAb anti-PCNA
antibody, using TUNEL assay and, for routine examination,
haematoxylin and eosin (HE)-stained sections.
Clinicopathological factors
The immunohistochemical findings were correlated with histolog-
ical type, depth ofinvasion (T), lymphatic involvement (N), distant
metastasis (M) and clinical stage. These were basically in accord
with the TNM classification (1987) (The Japanese Society for
Esophageal Diseases, 1992). The histological types of SCC can
vary within the same tumour. Usually, one tumourcontains multiple
sites with different differentiation. Therefore, the histological type
of the tumour was defined according to the predominant histolog-
ical finding in each case. The 34 oesophageal carcinoma tissues
were morphologically classified into eight well differentiated, 13
moderately differentiated, 11 poorly differentiated squamous cell
carcinomas and two undifferentiated carcinomas. The depth of
invasion was classified into four groups: TI, tumour invades lamina
propria or submucosa; T2, tumour invades muscularis propria; T3,
tumour invades adventitia; T4, tumour invades adjacent structure.
The lymphatic involvement and distant metastasis were classified
into two groups, positive and negative. No distant metastases were
observed in any ofthe tumours in this study.
Immunohistochemistry
Here, the avitin-biotin-peroxidase complex (ABC) method was
performed using the Vectastatin ABC Kit (Vector Laboratories,
Burlingame, CA, USA). Briefly, sections were deparaffinized in
xylene and rehydrated in a graded solution of ethanol. After
quenching the endogenous peroxidase activity in absolute
methanol containing 0.3% (w/v) hydrogen peroxide for 30 min,
non-specific binding was blocked by treatment with 1.5% (w/v)
normal horse serum (Vector) for 30 min. A polyclonal rabbit anti-
SKALP/elafin serum was applied to the sections at a dilution of
1:500, and each specimen was incubated in a moist chamber for
2 h at room temperature. Afterthe sections were washed three times
in 0.05 mol 1-' phosphate-buffered saline (PBS, pH 7.2), biotinyl-
ated anti-rabbit IgG (Vector) was applied at a dilution of 1:200.
The sections were again incubated for50 min at room temperature.
Freshly prepared ABC reagent (Vector) was applied and incubated
for 60 min after three washes in PBS. The localization of
SKALP/elafin was visualized by incubating the sections for 5 min
in freshly prepared 0.05 mol 1-' Tris-HCl (pH 7.6) containing both
0.02% (w/v) 3,3-diaminobenzidine tetrahydrochloride (Nakalai
Tesque, Kyoto, Japan) (DAB solution) and 0.03% (w/v) hydrogen
peroxidase. The control slides were prepared as follows: (1)
sections were processed without primary antibody; and (2) normal
rabbit serum and non-specific rabbit IgG were used instead of a
polyclonal anti-SKALP/elafin serum.
Immunohistochemical PCNA staining
Immunohistochemical PCNA staining was performed using the
Vectastatin ABC Kit (Vector). The sections were treated with 3%
hydrogen peroxidase for 30 min to block endogenous peroxidase
activity and were incubated with 1.5% (w/v) normal horse serum
to block non-specific binding of the antibody. They were incu-
bated with mouse monoclonal anti-PCNA antibody (CLA 16/1)
(Medac, Hamburg, Germany), diluted 1:200overnight at4°C, then
incubated with biotinylated rabbit anti-mouse IgG (Vector) for
30 min. Freshly prepared ABC Reagent-(Vector) was applied and
incubated for60 min. Finally, they were incubated with DAB solu-
tion containing 0.03% (w/v) hydrogen peroxidase. Between each
step, the sections were washed in PBS for 5 min three times and
then counterstained in Mayer's haematoxylin. The control slides
were prepared as follows: sections were processed without
primary antibody, and non-specific mouse IgG was used instead of
primary antibody.
TUNEL assay
The TUNEL assay was performed using the Apop Tag In Situ
Apoptosis Detection Kit (Oncor, Gaitherburg, MA, USA). Four-
micron-thick tissue sections were incubated with 20 mg ml' of
proteinase K (Boehringer, Mannheim, Germany) for 15 min at
room temparature. Digestion was stopped by washing in distilled
water four times. Sections were then incubated with TdT enzyme
(Oncor) containing potassium cacodylate as a buffer for 60 min at
37°C. Specimens were incubated with pre-warmed Stop/Wash
Buffer (Oncor) for 30 min at 37°C. After washing in three
changes of PBS for 5 min, specimens were incubated with anti-
digoxigenin peroxidase (Oncor) for 30 min at room temperature in
a humidified chamber. The reaction was visualized by adding
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Figure 1 (A) Immunohistochemical staining for SKALP/elafin in non-
malignant oesophageal mucosa. Positive staining of the cells in the stratified
zone adjacent to papillae of basal cells. No expression was found in the cells
of the basal zone. Pronounced submucosal inflammatory cell infiltration was
observed. Magnification xlOO. (B) Immunohistochemical staining for
SKALP/elafin in non-malignant oesophageal mucosa. No expression was
observed in a normal oesophageal mucosa. Magnification x40
Figure 2 Immunohistochemical staining for PCNA in non-malignant
oesophageal mucosa. The nuclei of hyperplastic cells in the basal zone were
stained. Magnification x200
DAB solution with 0.03% (w/v) hydrogen peroxide, and sections
were counterstained in methyl green for 10 min atroom temperature.
Positive control was treated with DNAase I (1 U ml-',
Boehringer) in 10 mmol 1-1 of Tris HCI, 10 mmol 1-1 sodium
chloride, 5 mmol 1-' ofMnCl2, 25 mmol 1-1 of potassium chloride,
pH 7.4 for 30 min at 37°C before DNA end labelling. For negative
controls, TdT enzyme was omitted from the reaction mixture.
Figure 3 (A) Immunohistochemical staining for SKALP/elafin in tumour cell
nests of well-differentiated squamous cell carcinoma of the oesophagus. The
cells underneath the cornified cells were stained. The walls of the cornified
cells were also stained. Magnification x200. (B) Immunohistochemical
staining for PCNA in a serial section of A. The nuclei of the cells in the basal
layer of the tumour cell nests were stained. Magnification x200. (C) DNA
fragmentation detected by the TUNEL assay in a serial section of A. DNA
fragmentation was visualized in a cell layer similar to the SKALP/elafin-
expressing cell layer. Magnification x200
Statistical analysis
Statistical comparison was performed using chi-squared tests;
P < 0.05 was considered to be significantly different.
RESULTS
Non-malignant oesophageal mucosa
Immunohistochemical expression of SKALP/elafin was occasion-
ally observed in non-malignant oesophageal mucosa. The expression
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Table 1 Relationship between the expression of SKALP/elafin and the
clinicopathological factors of the oesophageal carcinomas
Immunoreactivity
+ - P-value
Histology
Squamous cell carcinoma
Well differentiated 8 0
Moderately differentiated 11 2 P= 0.010
Poorly differentiated 6 5
Undifferentiated carcinoma 0 2
Depth of invasion
Ti (m,sm) 6 3
T2 (mp) 4 3 P=0641
T3 (al,a2) 13 3
T4 (a3) 2 0
Lymph node metastasis
N(+) 14 1 P=0.393
N ()9 1]
Histological stage
6
11 3 0 P=0310
III 9 3
IV 6 5
m, lamia propria; sm, submucosa; mp, muscularis propria; al, invasion
reaching adventitia; az, definite invasion to adventitia; a3, invasion into
neighbouring structures.
ofSKALP/elafin was found to be localized in the cells ofthe strati-
fied zone adjacent papillae of basal cells or overlying hyperplastic
basal zone (Figure 1). The expression was not found in the cells of
basal zone in any of the specimens. The areas that showed
SKALP/elafin expression were often found to be accompanied with
submucosal inflammatory cell infiltration or with mucosal damage
(Figure 1A). The expression was not observed in nonnal areas of
oesophageal mucosa and in the cells ofoesophageal glands (Figure
1B). The cytoplasmic granular pattern was most pronounced with
staining. The control slides were negative in all tissue samples
studied.
The expression of PCNA was observed in the cells of
oesophageal mucosa, accompanying the hyperplastic changes. In
most cases, the expression of SKALP/elafin and PCNA was
observed in the same area as non-malignant oesophageal mucosa.
However, the staining cell layers were clearly separated. PCNA
was expressed in the nucleus of the cells in papillae or in the
hyperplastic basal zone. In contrast, SKALP/elafin was expressed
in the cells of the stratified zone adjacent to PCNA-expressing
basal cells (Figure 2). No expression of SKALP/elafin was found
in the cells that expressed PCNA.
Oesophageal cancer
Of 34 oesophageal carcinomas examined, 25 (73.5%) showed
immunoreactivity with anti-SKALP/elafin serum. The staining
pattern varied from diffuse cytoplasmic to cytoplasmic granular.
Strong expression was observed in tumour cell nests that had a
clear squamous phenotype (Fig. 3A). Staining cells were localized
in the cell layerjust underneath the cornified cell layer of tumour
cell nests. As seen in non-malignant oesophageal mucosa, no
expression was observed in the cells of the basal layer in tumour
Figure 4 Immunohistochemical staining for SKALP/elafin in poorly
differentiated squamous cell carcinoma of the oesophagus. Positive staining
was localized in tumour cell nests with a clear squamous phenotype.
Magnification x40
cell nests. The wall ofthe cornified cells in tumour cell nests was
also found to be positive.
The relationship between the expression of SKALP/elafin and
the clinicopathological factors of oesophageal cancer is shown in
Table 1. The expression ofSKALP/elafin was significantly related
to the differentiation of the tumour. The expression of
SKALP/elafin was found in all eight (100%), in 11 out of 13
(84.6%), in 6 out of 11 (54.5%) and in none out oftwo (0%) spec-
imens of well, moderately, poorly differentiated squamous cell
carcinoma and undifferentiated carcinomarespectively. There was
an obvious relationship between the expression of SKALP/elafin
and the differentiation of squamous cell carcinoma of the oesoph-
agus. The incidence of the expression tended to be increased in
relation to the degree ofthe differentiation of the tumour. Even in
moderately or poorly differentiated squamous cell carcinoma, the
expression was observed only in cancer cells of tumour cell nests
showing a clear squamous phenotype (Figure 4). Undifferentiated
carcinoma cells did not express SKALP/elafin at all.
In this study, there was no relationship between the expression
of SKALP/elafin and other clinicopathological factors, such as
depth ofinvasion, lymph node metastases and histological stage.
In oesophageal cancer, PCNA was found to be expressed in all
specimens with variations in the number of positive cells and
staining intensity. In tumour cell nests, PCNA was found to be
expressed in the cells of the basal layer. The existence of
SKALP/elafin immunoreactivity in cancer cells overlying the
PCNA-expressing cell layer was observed in serial sections
(Figure 3B). As seen in non-malignant hyperplastic oesophageal
mucosa, both cell layers were clearly separated, and no expression
was found in the cells that expressed PCNA.
DNA fragmentation detected by the TUNEL method was also
found in all specimens with variations in the number of positive
cells and staining intensity. Characteristically, in tumour cell nests,
DNA fragmentation was found in the cells underneath the corni-
fled cell layer (Figure 3C). These cells were found to be similar to
the SKALP/elafin-expressing cells in serial sections.
DISCUSSION
We have demonstrated that SKALP/elafin immunoreactivity was
expressed in the mucosal area with submucosal inflammatory cell
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infiltration or with mucosal damage in non-malignant oesophageal
mucosa. The expression of SKALP/elafin was localized in the
cells adjacent to PCNA-expressing basal cells. The expression was
not observed in the cells ofnormal oesophageal mucosa nor in the
basal cells. These immunohistochemical findings observed in
this study correlate with previous findings on the presence of
SKALP/elafin immunoreactivity in normal and psoriatic skin. It
was found in the skin under inflammatory conditions but not in
normal skin (Schalkwijk et al, 1993), indicating that SKALP/elafin
could be induced in normal human skin underinflammatory condi-
tions or in the process of wound healing (Schalkwijk et al, 1991;
Alkemade et al, 1993).
It has been proved that SKALP/elafin inhibits the activities ofat
least three serine proteinases derived from polymorphonuclear
leucocytes (PMN), such as human leucocyte elastase, porcine
pancreatic elastase and human leucocyte proteinase 3 (Schalkwijk
et al, 1990, 1991; Wiedow et al, 1991). The secretion of SKALP/
elafin from cultured human keratinocytes has been found
(Molhuizen et al, 1993). Therefore, the present findings suggest
that SKALP/elafin could be produced and secreted from the squa-
mous cells of the oesophagus to protect the mucosa from PMN
serine proteinases under inflammatory conditions. Under these
circumstances, SKALP/elafin could act as a negative feedback on
the inflammatory response.
In the mucosal area showing hyperplastic changes, PCNA was
found in the nucleus ofhyperplastic basal cells; but no expression
of SKALP/elafin was observed in basal cells. The expression of
SKALP/elafin was limited in the cells of the stratified zone adja-
cent to PCNA-expressing basal cells. Thus it could be considered
to be involved in the regenerative/hyperproliferative differentia-
tion programme (Alkemade et al, 1993) rather than the normal
differentiation ofhuman oesophageal mucosa.
In oesophageal cancer, the incidence of the expression was
significantly related to the degree of the differentiation of the
tumour. The strong expression of SKALP/elafin was observed in
tumour cell nests that had a clear squamous phenotype accompa-
nied by clear keratinization. In moderately or poorly differentiated
squamous cell carcinoma, the expression was localized in tumour
cell nests and the expression was not found in poorly differentiated
or undifferentiated cells within these cancers. The present findings
suggest that the expression of SKALP/elafin is closely related to
the differentiation of squamous cell carcinoma of the human
oesophagus.
In this study, cytoplasmic staining was observed in the cancer
cells overlying PCNA-expressing cells in tumourcell nests. On the
other hand, the wall ofthe comified cells in tumour cell nests was
often found to be stained. Previous studies have shown that
SKALP/elafin exists in multiple forms (Schalwijk et al, 1991;
Alkemade et al, 1993; Molhuizen et al, 1993). The different forms
of SKALP/elafin have been reported to be generated by various
N-terminal deletions in squamous cell carcinoma and keratoacan-
thoma ofthe skin (Alkemade et al, 1993). The antisera used in this
study has been revealed to recognize all of these forms of
SKALP/elafin because the antisera was raised against a
SKALP/elafin fragment containing anti-proteinase activity and
which is located in the C-terminal half of the mature
SKALP/elafin molecule (Alkemade et al, 1993). Originally,
SKALP/elafin has been reported to be a proteinase inhibitor found
in psoriatic epidermis as a short polypeptide of6 kDa (Schalkwijk
et al, 1991; Molhuizen et al, 1993). Further purification and NH2-
terminal sequencing of SKALP/elafin from cultured keratinocytes
and the cloning of its cDNA has revealed that the existence of a
mature protein, which upon cleavage of a hydrophobic signal
sequence of 22 amino acids has a calculated molecular mass of
9.9 kDa (95 amino acids) (Molhuizen et al, 1993). The mature
protein contains a domain with fourrepeats which are homologous
to putative transglutaminase substrate motifs. It has been found
that both the complete SKALP molecule and a synthetic peptide of
the NH2-terminal portion of SKALP could be used as a transglut-
aminase substrate and is involved in the comified envelope forma-
tion (Molhuizen et al, 1993). Therefore, the staining of the cell
wall of the cornified cells in tumour cell nests suggests that
SKALP/elafin is involved in the comified envelope formation in
tumour cell nests ofoesophageal cancer. This finding also supports
the relationship between the expression of SKALP/elafin and the
cell differentiation ofsquamous cell carcinoma ofthe oesophagus.
As seen in non-malignant oesophageal mucosa, the expression
of SKALP/elafin was limited in the cells overlying PCNA-
expressing cells in tumour cell nests, and the expression was not
found in cells that expressed PCNA. In tumour cell nests, DNA
fragmentation was often observed in the same cell layers as those
in which SKALP/elafin was found. From these observations, it is
considered that SKALP/elafin may induce the cell differentiation
and further apoptosis of squamous cell carcinoma cells.
Furthermore, as no expression ofthis enzyme inhibitor was found
in poorly differentiated or undifferentiated cancer cells, lack of
production ofthis enzyme inhibitor may be involved in the malig-
nancy ofhuman squamous cell carcinoma ofthe oesophagus.
Several protease inhibitors, such as TIMPs (tissue inhibitor of
metalloproteases), PAI-I and PAI-2 (plasminogen activator
inhibitor type 1 and type 2), and urinary trypsin inhibitor have
been reported to possess the ability to inhibit cell growth and cell
invasion ofcarcinoma cells in vitro (Baker et al, 1990; Cajot et al,
1990; Albini et al, 1991; Declerck et al, 1992; Kennedy, 1994;
Kobayashi et al, 1994, 1995). Recently, transfection of maspin,
which is a newly purified seine protease inhibitor, has been
reported to reduce the malignancy ofbreast cancer cells (Zou et al,
1994). The present results together with previous findings suggest
that SKALP/elafin may possess the potential to reduce the malig-
nancy of human squamous cell carcinoma of the oesophagus and
could be a unique tool for the development of a new therapeutic
method against this lethal neoplasm.
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